Condition: Beta-Thalassemia · Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
This is a phase Ib, randomized, double-blind, placebo-controlled, multiple ascending dose study . The objectives of the study are to evaluate the safety , tolerability, pharmacokinetics(PK), pharmacodynamics(PD), and immunogenicity of 9MW3011 in patients with non-transfusion-dependent β- thalassemia .
This description comes directly from the study's public registry record.
Yongrong Lai · +8607715356304 · laiyongrong@hotmail.com
Always discuss trial participation with your own doctor first.
| The first Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | Recruiting |
| Hainan General Hospital | Haikou, Hainan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06772766